Viruses Pg 3 - 7 Flashcards
(37 cards)
(1) Cough, runny nose -> generalized aches and muscle pain, fever
(possible nausea and vomiting in children probably due to fever)
(2) Incubation 1-2 days; symptoms 5-7 days (cough 7-14 days)
Influenza virus (Myxovirus)
(3) Viral Pneumonia (about 10% of admissions) – high mortality
(4) Secondary Bacterial Pneumonia sometimes follows viral URT infections
b. Transmitted by droplets and contact (especially hands) and by inhalation
Influenza virus (Myxovirus)
d. Virus Structure
(1) Core with 8 strands of RNA
(2) Envelope
(a) Lipid bilayer from previous host cell (animal specific or adapted to other types of cells)
(b) Hemagglutinin and Neuraminidase – used for attachment and virulence
(3) Matrix protein (capsid)
Influenza virus (Myxovirus)
Influenza virus (Myxovirus) has a core with?
8 strands of RNA
Describe the Influenza virus (Myxovirus) envelope
LIpid bilayer from the PREVIOUS host cell, which means its animal-specific or adapted to other types of cells
The envelope uses hemagglutinin and neuraminidase for attachment and virulence
Hemagglutinin and Neuraminidase
envelope/virulence for Influenza virus (Myxovirus)
Also the surface antigens
(1) Types based on surface antigens Hemagglutinin (H) and Neuraminidase (N)
(a) Animal strain based on original “source” of viral envelope
(b) Infectivity of animal virus to humans is due to adaptation to enter human cell membranes
Antigenic Types (A, B, C) types of Influenza virus (myxovirus)
(a) Common human subtypes: H3N2, H1N1 (human strain)
(b) Numerous swine subtypes, some adapted to humans, e.g. 2009 H1N1 (highly transmissible)
(c) Numerous avian subtypes, some adapted to humans; e.g. emerging subtype H5N1, H7N9 (considered dangerous)
Type A influenza
Influenza types B and C are antigenically ____?
Stable
Virulence factors for flu?
Gene recombination and mutation
Hemagglutinin and Neuraminidase are factors both of attachment and cause some symptoms
High rate of gene recombination and mutation – New major antigenic types and subtypes sweep the world every 2-4 years
virulence for Influenza virus (Myxovirus)
Influenza virus (Myxovirus) Surface antigen changes due to:
gene recombination and gene mutation
recombination of 8 strands of RNA
gene recombination
Influenza virus (Myxovirus)
causes antigenetic shift and drift
Gene mutation
Influenza virus (Myxovirus)
factors both of attachment and cause some symptoms
Hemagglutinin and Neuraminidase
Influenza virus (Myxovirus)
(a) Animal-specific envelope (e.g. human strains infect humans; avian strains infects avians; swine strains)
(b) Surface antigen changes (e.g. Avian Influenza (H5N1)
(c) Adaptation of virus envelope to enter and replicate in human cell
Other virulence factors…
Influenza virus (Myxovirus)
Antiviral (for influenza/myxovirus) medications available – start treatment within __ hours to be effective
48
Vaccine for Influenza virus (Myxovirus)?
(1) Made with the most common 3 antigens
(2) Required annually to match antigenic strains moving toward USA (World Health Org., CDC, and DoD labs track location and movement of strains around the world)
RNA viruses that cause common cold?
THESE THREE FOR COMMON COLD testing purposes
Rhinovirus, Respiratory Syncytial Virus (RSV), and Corona virus
overall most prevalent agent (over 160 antigen types) of cold
rhinovirus
Second most common agent of colds
corona virus
(b) Multiple antigenic types (about 30 types)
(c) New Highly Virulent Variants in Recent Years
- SARS (Severe Acute Respiratory Syndrome) (several thousand cases, about 30% mortality)
- MERS-CoV (Middle East Respiratory Syndrome – Corona Virus) – severe acute respiratory illness (fever, cough, shortness of breath), several hundred persons ill and about 30% mortality since 2012 (mostly Jordan, Saudia Arabia); camels are likely source
corona virus
aka Human Orthopneumovirus, - the primary agent of colds in infants and young children
Respiratory Syncytial Virus (RSV)
(a) Hundreds (thousands ?) of antigenic types exist; Antigenic groups A and B
(b) Can cause severe infections
(c) Immunoglobulins are not necessarily protective against future infections
(d) Development of vaccine is very challenging
Respiratory Syncytial Virus (RSV)